Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li><keyword id="8830896" type="UNKNOWN" weightage="20" keywordseo="Rossari-Biotech">Rossari Biotech</keyword> — the chemicals company that had a blockbuster IPO in 2020 — is planning to acquire its peer company <keyword id="11369058" type="COMPANY" weightage="20" keywordseo="unitop-chemicals">Unitop Chemicals</keyword> for ₹421 crore.</li><li>The company’s share price is up by 2.5% on June 3 after announcing its plans.</li><li>Operating in the same sector, Rossari can add Unitop Chemicals’ production capacity of 86,000 million tonnes per year to its own without having to make too many changes.</li><li>Rossari will be digging into its own coffers to fund the transaction with 65% equity being acquired on closure and the rest coming in over the next two years.</li></ul>Rossari Biotech — the maker of household products like Vim, Rin and Surf for brands owners like <keyword id="6365619" type="COMPANY" weightage="20" keywordseo="hindustan-unilever">Hindustan Unilever</keyword>, Dabur and others — has announced plans to acquire its peer Unitop Chemicals for a sum total of ₹421 crore. The company’s share price is up by 2.5% as of 12:30pm on June 3, after the announcement. "We believe the acquisition will be EPS [earnings per share] accretive for Rossari," said Edelweiss in its report dated June 2. Simply put, the financial services company believes that Unitop and Rossari are a good fit and the acquisition will result in gradual growth. <div type="image" title="infibeam share price(1)" msid="83198900" hostid="261" caption="&amp;lt;p&amp;gt;Rossari Biotech stock since the launch of its IPO in July 2020&amp;lt;/p&amp;gt;"></div> As per the plan approved by the board, Rossari will be buying up 100% of Unitop Chemicals’ equity capital. 65% of it will be acquired upon closure of the transaction and the rest will be balanced over the next two years. “Unitop Chemicals is a natural fit with our operations and brings with it immense synergies and complementary growth dimensions,” said Rossari’s executive chairman Edward Menezes and managing director Sunil Chari in a joint statement. <cmsannotation type="cmsannotation" annotationid="Here’s what Rossari will gain from Unitop" comment="subhead" text="Here’s what Rossari will gain from Unitop">Here’s what Rossari will gain from Unitop</cmsannotation> Since both companies are in the chemical manufacturing space, they use similar technology, require the same talent in their employees and dabble in the same verticals. For instance, Unitop Chemicals’ expertise is in manufacturing surfactants — the kind found in detergents, wetting agents, emulsifiers, and so on. This is one of Rossari’s four core chemistries. Moreover, Unitop Chemicals has three manufacturing sites and its main facility in Dahej is near Rossari’s existing facility in the area. Overall, Rossari will be able to capitalise on Unitop’s production capacity of 86,000 million tonnes per annum (MTPA) to boost its own output. And, while the two companies work in the same arena, there is little overlap in end-users. This means Unitop Chemicals' customers will be an entirely new set of clients for Rossari to monetise with cross-selling and will help expand the company's market reach. Wodehouse Capital was the exclusive financial advisor to Unitop Chemicals for the deal. Rossari does not plan on raising any debt for this transaction. It will be funding the investment using the cash it already has on its balance sheets. In April, Rossari raised ₹300 crore through the preferential issue of equity shares. This is after the company went public in July 2020 and was one of the hottest initial public offerings (IPO) of the year, listing at a premium of 59%. SEE ALSO: <a href="https://www.businessinsider.in/business/corporates/news/backed-by-mukesh-ambani-infibeam-expects-business-to-grow-manifold-to-100-billion-dollars/articleshow/83111869.cms">INTERVIEW: With a partner like Mukesh Ambani's Jio, Infibeam expects to hit $100 billion in online transactions in the next 5 years</a> <a href="https://www.businessinsider.in/stock-market/economy/news/indias-gdp-has-contracted-five-times-since-1947-but-never-as-bad-as-7-3/articleshow/83135455.cms">India’s GDP has contracted five times since 1947, but never as bad as 7.3%</a> <a href="https://www.businessinsider.in/business/corporates/news/infosys-new-insider-trading-case-shows-that-employees-made-rs-3-crore/articleshow/83144170.cms">Here's how Infosys employees shared insider information that turned a chunky profit of ₹3 crore</a>

Here's why Rossari Biotech bought Unitop Chemicals for ₹421 crore

<ul><li>Indian IT behemoth <keyword id="10862" type="CITY" weightage="20" keywordseo="Wipro">Wipro</keyword> touched the ₹3 lakh crore market cap milestone on June 3.</li><li>Thursday’s high comes after the company announced its new partnership with Finastra, a fintech giant that serves 90 of the top 100 banks globally.</li><li>With Wipro focusing on the banking sector, the company’s stock has rallied by over 31% with TCS, <keyword id="6354512" type="COMPANY" weightage="20" keywordseo="Infosys">Infosys</keyword>, HCL Tech and Tech Mahindra showing muted share price movement in the last two months.</li></ul>The Indian information technology (IT) giant, Wipro, touched the ₹3 lakh crore ($41 billion) market cap milestone in early trade on June 3. In the last two months, its stock has far outperformed its peers. <div type="image" title="wipro share price chart" msid="83223480" hostid="261" caption="&amp;lt;p&amp;gt;Wipro&amp;#39;s share price from 1 April 2021 to 3 June 2021&amp;lt;/p&amp;gt;"></div> Wipro’s share price has rallied by over 31% since April 1, whereas the stocks of other IT companies — Tata Consultancy Services (TCS), Infosys, HCL Tech and Tech Mahindra — have, more or less, stagnated. Among top five IT players in India, HCL Tech was the worst performing with its share price dipping by nearly 6%. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Increase in share price since 1 April 2021 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Wipro </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">31% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tech Mahindra </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2.5% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">TCS </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1.2% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Infosys </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-0.4% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HCL Tech </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-5.9% </td></tr></tbody></table>Source: Compiled using BSE data <cmsannotation type="cmsannotation" annotationid="Wipro is expected to bring in more revenue than its peers this year" comment="subhead" text="Wipro is expected to bring in more revenue than its peers this year">Wipro is expected to bring in more revenue than its peers this year</cmsannotation> In the fourth quarter, Wipro net profit grew by 27% as compared to the same three months the year before. This was the company’s best result in nearly a decade. The last time it delivered double-digit growth in its quarterly net profit was in FY16. Barring Wipro, most IT companies have seen muted share price movement since the results of the previous financial year came out. <div type="image" title="it share price chart" msid="83223517" hostid="261" caption="&amp;lt;p&amp;gt;Performance of the top 5 Indian IT companies over the last two months&amp;lt;/p&amp;gt;"></div> However, all five of the top IT companies in India are bullish about their prospects in the ongoing financial year. Riding the wave of outsourcing and cloud adoption, IT players are aiming for double-digit revenue growth. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Company </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revenue guidance (in constant currency terms) </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Operating margin guidance </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">TCS </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Does not issue guidance </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Does not issue guidance </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Infosys </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">12-14% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">22-24% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HCL Tech </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Double-digit growth </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">19-21% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Wipro </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">8-10% </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;"> </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tech Mahindra </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Double-digit growth in enterprise, and single digit growth in telecom </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Less than 15% </td></tr></tbody></table> With its focus on growing the banking, financial services and insurance segment (BFSI), expected recovery in manufacturing, and lead in healthcare, analysts predict that Wipro will deliver higher revenue growth than its peers over the next two years. <div type="image" title="it cos Fy22 fy23 expected revenue increase" msid="83223553" hostid="261" caption="&amp;lt;p&amp;gt;Expected revenue growth of top 5 Indian IT companies in India in FY 22 and FY 23&amp;lt;/p&amp;gt;"></div> Wipro management disclosed they don’t see overall spending coming down anytime soon, during the fourth-quarter earnings call. Cloud solutions account for 25% to 30% of Wipro’s revenue and it is growing much faster than the average growth of the company. <cmsannotation type="cmsannotation" annotationid="What is driving Wipro’s share price rally?" comment="subhead" text="What is driving Wipro’s share price rally?">What is driving Wipro’s share price rally?</cmsannotation> Wipro has seen a flurry of activity this week. The jump in Wipro’s share price comes after the IT giant announced its new partnership with Finastra — a fintech giant that serves 90 of top 100 banks globally — to help its client banks with their digital transformation. Wipro said that the new partnership is focused on its clients in the Asia-Pacific region. This includes India’s largest public sector bank — the State Bank of India (SBI) — and ING Australia, the fourth biggest bank on the island nation. The company also sold its entire stake in Denim Group, a application security firm, for a consideration of $22.42 million. That’s triple what Wipro paid for its 33.33% stake back in march 2018. Furthermore, the enterprise picked up a minority stake in Squadcast, an incident response platform that helps software engineers do on-call scheduling, for $1.2 million. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/indusind-bank-shares-slide-as-a-year-old-cayman-islands-order-against-hinduja-bank-resurfaces/articleshow/83197693.cms">IndusInd Bank shares slide as a year-old Cayman Islands order against Hinduja Bank resurfaces</a> <a href="https://www.businessinsider.in/science/health/news/the-indian-government-is-doling-out-1500-crore-to-reserve-300-million-of-biological-es-covid-19-vaccine-doses/articleshow/83196362.cms">The Indian government is doling out ₹1500 crore to reserve 300 million of Biological-E’s COVID-19 vaccine doses</a> <a href="https://www.businessinsider.in/business/corporates/news/rossari-biotech-to-acquire-peer-unitop-chemicals-for-421-crore-this-will-ramp-up-its-production-capacity-by-86000-million-tonnes-a-year/articleshow/83176380.cms">Here's why Rossari Biotech bought Unitop Chemicals for ₹421 crore</a>

Wipro outshines TCS, Infosys and others with a 31% jump in share price over the last two months

Observing courts cannot be "silent spectators" when <keyword id="2161398" type="PERSON" weightage="20" keywordseo="constitutional-rights">constitutional rights</keyword> of citizens are infringed by <keyword id="11370537" type="UNKNOWN" weightage="20" keywordseo="executive-policies">executive policies</keyword>, the <keyword id="6354977" type="COMPANY" weightage="20" keywordseo="Supreme-Court">Supreme Court</keyword> on Wednesday slammed the Centre's <keyword id="10997839" type="UNKNOWN" weightage="20" keywordseo="covid-vaccination-policy">COVID vaccination policy</keyword>, describing as "prima facie arbitrary and irrational" allowing states and private hospitals to charge those in the 18-44 age group while the jabs were offered free for groups in the first two phases, and ordered its review. Seeking to scrutinise the <keyword id="8764262" type="COMPANY" weightage="20" keywordseo="covid">COVID</keyword> vaccination policy in detail, the top <keyword id="6355578" type="COMPANY" weightage="20" keywordseo="court">court</keyword> also asked the Centre to provide information including as to how ₹35,000 crore, earmarked for vaccines, has been spent so far, and to place on record all relevant documents and file notings reflecting its thinking culminating in the policy. The apex court's May 31 order, uploaded on its site on Wednesday, was critical of the Centre's decisions on liberalized vaccination policy, differential pricing of vaccines for Centre, states and private hospitals, basis of such a norm and mandatory registration on CoWIN App for booking slots for jabs in view of huge digital divide between rural and urban India and sought response from the government on its queries in in two weeks. The apex court said that in grappling with the second wave of the COVID pandemic, it does not intend to second-guess the wisdom of the executive when it chooses between two competing and efficacious policy measures. The court, however, added that it will continue to exercise jurisdiction to determine "if the chosen policy conforms to the standards of reasonableness, militates against manifest arbitrariness and protects the right to life of all persons". "Constitution does not envisage courts to be silent spectators when constitutional rights of citizens are infringed by executive policies", the bench said in its order in a hard hitting response to the Centre's submissions in an affidavit that the judiciary should not enter into the policy making domain. "The Union Budget for Financial Year 2021-2022 had earmarked ₹35,000 crore for procuring vaccines. In light of the Liberalized Vaccination Policy, the <keyword id="6357307" type="COMPANY" weightage="20" keywordseo="Central-Government">Central Government</keyword> is directed to clarify how these funds have been spent so far and why they cannot be utilized for vaccinating persons aged 18-44 years," said a special bench of Justices D Y Chandrachud, L Nageswara Rao and S Ravindra Bhat. "We direct the Union of India(UoI) to undertake a fresh review of its vaccination policy addressing the concerns raised," said the order which is a part of a series of judicial decisions rendered on the suo motu case on COVID-19 management in the country. Finding fault with the vaccination policy, it said unlike the previous one, it did not prioritize persons with comorbidities and this became important in view of the fact that in the second wave, persons between 18-44 years of age have suffered severe effects of infection including deaths in unfortunate cases. "Due to the changing nature of the pandemic, we are now faced with a situation where the 18-44 age group also needs to be vaccinated, although priority may be retained between different age groups on a scientific basis. "Hence, due to the importance of vaccinating individuals in the 18-44 age group, the policy of the Central Government for conducting free vaccination themselves for groups under the first 2 phases, and replacing it with paid vaccination by the State/UT Governments and private hospitals for the persons between 18-44 years is, prima facie, arbitrary and irrational," Justice Chandrachud said in the 32-page order. <keyword id="6354525" type="COMPANY" weightage="20" keywordseo="healthcare">Healthcare</keyword> workers and those above 45 years figured in the first two phases. The court asked the Centre to provide the data on the percentage of population that has been vaccinated (with one dose and both doses), as against eligible persons in the first three phases of the vaccination drive. "This shall include data pertaining to the percentage of rural population as well as the percentage of urban population so vaccinated," it said asking the Centre to furnish each and every detail sought. The bench also sought "complete data" of the Centre's purchase history of all the COVID-19 vaccines-- <keyword id="9485939" type="PERSON" weightage="20" keywordseo="covaxin">Covaxin</keyword>, <keyword id="9617748" type="LOCATION" weightage="20" keywordseo="covishield">Covishield</keyword> and Sputnik V-- till date. "The data should clarify: (a) the dates of all procurement orders placed by the Central Government for all 3 vaccines; (b) the quantity of vaccines ordered as on each date; and (c) the projected date of supply; and an outline for how and when the Central Government seeks to vaccinate the remaining population in phases 1, 2 and 3." The court has sought information on the steps being taken by the Centre to ensure drug availability for mucormycosis which is also called 'Black Fungus'. Taking note of the Centre's reply that states and UTs will provide vaccination free of cost to its population, the court said it is important that individual states and UTs may "confirm or deny" this position before this Court. "Further, if they have decided to vaccinate their population for free then, as a matter of principle, it is important that this policy is annexed to their affidavit, so that the population within their territories can be assured of their right to be vaccinated for free at a state vaccination centre. "Hence, we direct each of the State/UT Governments to also file an affidavit within 2 weeks, where they shall clarify their position and put on record their individual policies," the bench said. Trashing the Centre's objection that judiciary should not enter into the policy making domain, the bench said it is trite to state that separation of powers is a part of the basic structure of the Constitution and policy-making continues to be in the sole domain of the executive. "The judiciary does not possess the authority or competence to assume the role of the executive, which is democratically accountable for its actions and has access to the resources which are instrumental to policy formulation. However, this separation of powers does not result in courts lacking jurisdiction in conducting a judicial review of these policies. "Our Constitution does not envisage courts to be silent spectators when constitutional rights of citizens are infringed by executive policies. Judicial review and soliciting constitutional justification for policies formulated by the executive is an essential function, which the courts are entrusted to perform." The top court asked the Centre to clarify its stand on the roadmap of the projected availability of vaccines till 31 December 2021, the preparedness with respect to specific needs of children in the event of a third wave of the pandemic in terms of medical infrastructure, vaccination trials and regulatory approval, and compatible drugs. It has sought information whether under the Centre's policy, it is permissible for the states and UTs or individual local bodies to access vaccine supplies of foreign manufacturers. The court also sought numbers of crematorium workers vaccinated in phase one and asked whether a targeted drive can be conducted for vaccination of the remaining workers in this category. "The State/UT Governments are diverting the vaccines (procured by them at a higher price than Central Government) for the persons in the age group of 18-44 years to vaccinate persons above 45 years of age, due to a shortage of vaccines being supplied by the Central Government. "The manner in which the Central Government will factor this quantity and price differential into their subsequent allocation and disbursal of vaccines to States/UTs for the persons above 45 years of age; and the mechanism for redistribution, if the 25:25 quota in a particular State/UT is not picked up by the State/UT Government or the private hospitals," the order said while seeking details. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/rossari-biotech-to-acquire-peer-unitop-chemicals-for-421-crore-this-will-ramp-up-its-production-capacity-by-86000-million-tonnes-a-year/articleshow/83176380.cms">Rossari Biotech to acquire peer Unitop Chemicals for ₹421 crore — this will ramp up its production capacity by 86,000 million tonnes a year</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/logistics-startup-locus-raises-50-million-in-series-c-aims-to-double-its-patents-by-2022-to-hire-more-data-scientists/articleshow/83176106.cms">Logistics startup Locus raises $50 million in Series C — aims to double its patents by 2022, to hire more data scientists</a>

Supreme Court slams Centre's COVID-19 vaccination policy for being 'arbitrary and irrational' — demands to know details on money spent on vaccine shots

You Searched For "unitop chemicals" and got 3 results

Here's why Rossari Biotech bought Unitop Chemicals for ₹421 crore

Prabhjote Gill

Wipro outshines TCS, Infosys and others with a 31% jump in share price over the last two months

Prabhjote Gill

Supreme Court slams Centre's COVID-19 vaccination policy for being 'arbitrary and irrational' — demands to know details on money spent on vaccine shots

PTI

Popular Keywords

Buying Guides